Biocorp Production

Biocorp Production Gross Margin

Delisted

The Gross Margin of Biocorp Production (ALCOR.PA) as of Oct 27, 2026 is 50.89 %. In the previous year, Gross Margin was 58.68 % — a change of -13.28% (lower).

Gross Margin

50.89 %

YoY

-13.28%

Last updated:

Gross Margin of Biocorp Production is 2022 50.89 % . Gross Margin of Biocorp Production was 2021 58.68 % . It decreases by -13.28% lower compared to the previous year.

For Biocorp Production, the gross margin of 50.9% is up versus -13.2% a few years ago.

The Biocorp Production Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2015
-26.73 EUR
Jan 1, 2016
-13.83 EUR
Jan 1, 2017
-43.06 EUR
Jan 1, 2018
-13.16 EUR
Jan 1, 2019
60.01 EUR
Jan 1, 2020
42.76 EUR
Jan 1, 2021
58.68 EUR
Jan 1, 2022
50.89 EUR
The Biocorp Production Gross Margin history
YEARGross MarginYoY
50.89 %-13.28%
58.68 %+37.22%
42.76 %-28.74%
60.01 %-556.03%
-13.16 %-69.44%
-43.06 %+211.29%
-13.83 %-48.25%
-26.73 %+21.56%
-21.99 %-140,368.46%
0.02 %-95.15%
0.32 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biocorp Production Stock analysis

What does Biocorp Production do? Biocorp Production SA is a French company in the medical technology industry that manufactures innovative solutions for drug administration and injections. It was founded in 2004 under the name Biocorp sur mesure by Eric Dessertenne and later transformed into Biocorp Production SA. The business model of Biocorp Production SA is to produce innovative medical devices that can be used in medical applications. The company specializes in the development of smart devices that support injection administration. The devices produced by Biocorp can be operated by medical professionals or by patients themselves. One of the core areas of Biocorp Production SA is the development of smart medical technologies that aid in medication management. One such product is Vyoo, a device that assists patients in injecting medications. It is a digital device that facilitates injection administration and makes dosing safer. In addition to developing smart devices, Biocorp also offers other services, such as in the field of clinical trials for medical applications. The company works closely with pharmaceutical companies to develop medical devices and solutions for drug administration. Another important product is Mallya, an intelligent insulin administration system specifically designed for diabetes patients. It enables automated insulin administration tailored to the patient's needs, thereby improving their quality of life. Furthermore, Biocorp Production SA is also involved in the field of wearable medical technology. One example of a wearable device is Easylog, an electronic device for monitoring medical conditions. This device is particularly useful for patients with chronic diseases such as diabetes or asthma. Over the years, Biocorp Production SA has received numerous awards for its innovative products and services. For example, the company received the Innovation Award at the "Innovation Awards" in Paris in 2017 for the Mallya device. Overall, the company currently employs over 60 employees and has its headquarters in Issoire. It has branches in Germany and the USA. The products of Biocorp Production SA are sold in more than 80 countries worldwide. In summary, Biocorp Production SA is a leading provider of smart medical devices for drug administration and injections. The company strives to develop innovative solutions for the medical industry that are tailored to the needs of patients and medical professionals. With the products of Biocorp Production SA, medication administration becomes safer, easier, and more accurate. Biocorp Production is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biocorp Production stock

Gross Margin of Biocorp Production is 50.89 % in 2022.

Gross Margin of Biocorp Production changed from 58.68 % to 50.89 %, representing a -13.28% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin Biocorp Production since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Biocorp Production with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Biocorp Production

All Key Metrics — Biocorp Production